CN100408058C - Stomach-power Chinese medicine preparation and preparing method - Google Patents

Stomach-power Chinese medicine preparation and preparing method Download PDF

Info

Publication number
CN100408058C
CN100408058C CNB2005100600232A CN200510060023A CN100408058C CN 100408058 C CN100408058 C CN 100408058C CN B2005100600232 A CNB2005100600232 A CN B2005100600232A CN 200510060023 A CN200510060023 A CN 200510060023A CN 100408058 C CN100408058 C CN 100408058C
Authority
CN
China
Prior art keywords
preparation
parts
drying
gained
radix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2005100600232A
Other languages
Chinese (zh)
Other versions
CN1742820A (en
Inventor
方铝
张爱华
张俊明
钟小群
张建荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yintao Pharmaceutical Industry Co., Ltd., Jiangxi
Original Assignee
YINTAO PHARMACEUTICAL INDUSTRY Co Ltd JIANGXI
Jiangxi Medicine Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by YINTAO PHARMACEUTICAL INDUSTRY Co Ltd JIANGXI, Jiangxi Medicine Research Institute filed Critical YINTAO PHARMACEUTICAL INDUSTRY Co Ltd JIANGXI
Priority to CNB2005100600232A priority Critical patent/CN100408058C/en
Publication of CN1742820A publication Critical patent/CN1742820A/en
Application granted granted Critical
Publication of CN100408058C publication Critical patent/CN100408058C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a 'Liuwei digestion stabilizing preparation' for treating gastralgia, gasteremphraxis, dyspepsia, astriction and dysmenorrhea, which belongs to a traditional Chinese medicine preparation for enhancing gastric motility. The preparation of the present invention is prepared from raw materials, such as elecampane, rhubarb, galanga resurrectionlily rhizome, calcined gypsum lamelliforme, fructus chebulae and trona through the modern advanced technology methods, such as a penetrating method, a concentrating method, a drying method, etc. The medicinal preparation of the present invention overcomes the disadvantages that in the 'original Liuwei digestion stabilizing capsule' preparation, because the production technology is coarse, finished product bacteria and heavy metals are easy to exceed standard, the dosage is large, the dependence of patients is poor, etc. The present invention also relates to a preparation method of the medicinal preparation of the present invention. Compared with the 'original Liuwei digestion stabilizing capsule' preparation, the present invention has the advantages that the dosage is reduced half, and the quality standard is further perfected and improved. The pharmacodynamics research indicates that the medicinal preparation of the present invention has the functions of enhancing the gastric motility of a mouse, alleviating pain, protecting the gastric mucosa of a rat and promoting the gastric secretion of the rat.

Description

A kind of gastric motility Chinese medicine preparation and preparation method thereof
Technical field
The present invention relates to a kind of treatment stomachache distension, dyspepsia, constipation, gastric motility Chinese medicine preparation--the LIUWEIANXIAO ZHIJI of dysmenorrhea.Be on the prescription basis of existing Chinese patent medicine " LIUWEIANXIAO JIAONANG ", to adopt advanced processing technology and the refining medicine that forms of technology specifically.And, proved that medical instrument of the present invention has tangible gastric motility effect by pharmacodynamics test.The invention still further relates to the preparation method of this medicine.
Background technology
As everyone knows, quickening day by day along with rhythm of life, and the edge of Bad Eating Habit in all parts of the country is continuous, factor such as eating and drinking too much at one meal in addition, the sickness rate of gastroenteropathy is high all the time, in various gastropathy, a kind of gastropathy of functional dyspepsia by name has risen to first in the gastropathy.Owing to food stagnation is stagnated and to be produced the stomach distension, qi depression to blood stasis causes gastralgia, the dysfunction of the spleen and produces dyspepsia.Though functional dyspepsia can not cause Gastric Diseases by Spraying, stomachache repeatedly, abdominal distention can seriously be disturbed normal work and life.For a long time people to use medicine for stomach dynamic mostly be metoclopramide, motilium, Pu Ruiboen of Western medicine etc., the side effect of the clinical common central nervous system of the medicine for stomach dynamic of Western medicine, hormonal system can not be taken for a long time in large quantities.Therefore, people wish can develop the Chinese patent medicine with stomach motility enhancing effect in Chinese medicine, and both adjustable gastric bowel movements can make restoration of gastrointestinal function and cure diseases again, and toxic and side effects are again little.Often the Chinese physician reaches this therapeutic purposes by opening Chinese medicinal formulae clinically.And the Chinese patent medicine that clear and definite stomach motility enhancing arranged really seldom.LIUWEIANXIAO JIAONANG be according to the Mongols, Tibetan wide-spread and evident in efficacy through proved recipe, and the medicine of the treatment gastric indigestion that forms of the development of clinical studies surplus 30 year, we take in " Chinese pharmacopoeia version in 1985,1990,1995 and 2000.LIUWEIANXIAO JIAONANG is that Six-element medical materials such as Radix Inulae, Radix Et Rhizoma Rhei, Rhizoma Kaempferiae, Gypsum Rubrum (calcined), Fructus Chebulae, trona are through directly pulverizing the capsule that packing forms.This medicine exists the finished product antibacterial, heavy metal easily exceeds standard because production technology is coarse, and because of dose big (every of LIUWEIANXIAO JIAONANG is adorned 0.5 gram, oral one time 3~6,2~3 times on the one) and the shortcomings such as compliance difference that cause the patient to take medicine.
Summary of the invention
The objective of the invention is in order to overcome that finished product antibacterial, heavy metal that LIUWEIANXIAO JIAONANG slightly causes owing to production technology easily exceed standard and shortcoming such as the big patient's compliance of dose difference, we adopt the modern science and technology method to extract, separate, former preparation is made with extra care, be developed into a kind of safe and effective, quality controllable, and dose is little, ill acceptable gastric motility Chinese medicine preparation " LIUWEIANXIAO ZHIJI ", and prove that by pharmacodynamic experiment it has tangible gastric motility effect.Another object of the present invention provides the preparation method of medicine of the present invention.
The present invention is achieved in that
Prepare drug prescription of the present invention and form by weight that its proportioning is:
65~155 parts of 130~300 parts of Rhizoma Kaempferiae of 30~70 parts of Radix Et Rhizoma Rhei of Radix Inulae
210~410 parts of 110~210 parts of trona of 145~360 parts of Fructus Chebulaes of Gypsum Rubrum (calcined).
The formula optimization weight ratio scope of preparation medicine of the present invention is:
85~135 parts of 160~240 parts of Rhizoma Kaempferiae of 40~60 parts of Radix Et Rhizoma Rhei of Radix Inulae
240~360 parts of 130~170 parts of trona of 195~295 parts of Fructus Chebulaes of Gypsum Rubrum (calcined).
The prescription optimum weight ratio scope of preparation medicine of the present invention is:
250 parts of 100 parts of Gypsum Rubrum (calcined) of 200 parts of Rhizoma Kaempferiae of 50 parts of Radix Et Rhizoma Rhei of Radix Inulae
300 parts of 150 parts of trona of Fructus Chebulae.
The preparation method that above-mentioned each component is made medicine of the present invention is as follows:
1, Gypsum Rubrum (calcined) is ground into fine powder, it is standby to cross 40~100 mesh sieves;
2, after trona makes dissolving with 2~8 times of water gaging heating decoctions, filter, filtrate concentrates, and dry thing is standby;
3, Radix Inulae, Radix Et Rhizoma Rhei, Rhizoma Kaempferiae and Fructus Chebulae powder are broken into coarse powder, make solvent with 60~95% ethanol, flood and carry out percolation after 12~72 hours, collect the liquid of filtering, percolate is concentrated into the thick paste shape after reclaiming ethanol;
4, (3) gained thick paste is added (1) gained fine powder, mixing, drying under reduced pressure;
5, the dry thing of (4) gained is added the refining thing of (2) gained trona, be ground into fine powder;
6,, make acceptable various dosage forms on the pharmaceutics according to a conventional method with above-mentioned dry thing.
The dosage form of medicine of the present invention comprises for example capsule, granule, tablet, oral liquid, pill, suspensoid, drop pill, pellet, buccal tablet, soft gelatin capsule, soft capsule, dispersible tablet, solution, aerosol, spray, cataplasma, patch etc.
Above-mentioned preparation technology's condition is characterized in that:
Method for concentration can be to concentrate under the normal pressure, as usually depresses water-bath and concentrates; Also can be concentrating under reduced pressure, the concentrating under reduced pressure condition be: 0.01~0.09MPA, 40~90oC;
Reclaiming the ethanol method can be that normal pressure reclaims, and also can be reclaim under reduced pressure, and the decompression recycling ethanol condition is: 0.01~0.09MPA, 30~80oC;
Drying means can be: contact drying, pneumatic conveying drying, tunnel type oven drying, vacuum (decompression) drying, airpillow-dry, spray drying, lyophilization, far-infrared ray drying, microwave drying.
Beneficial effect of the present invention shows:
Compare with former preparation " LIUWEIANXIAO JIAONANG ", dose has reduced half; Quality standard has obtained further improving and improving; Drug efficacy study shows that medicine LIUWEIANXIAO ZHIJI of the present invention has the mice gastric motility of enhancing and analgesic effect, has the protection gastric mucosa of rat and promotes the excretory effect of rat gastric juice.
1, medicine of the present invention " LIUWEIANXIAO ZHIJI " compares with former preparation " LIUWEIANXIAO JIAONANG ", and dose has reduced half (seeing Table 1)
Table 1 LIUWEIANXIAO ZHIJI and former preparation " LIUWEIANXIAO JIAONANG " dose are relatively
Figure C20051006002300071
2, medicine of the present invention " LIUWEIANXIAO ZHIJI " compares with former preparation " LIUWEIANXIAO JIAONANG ", and quality standard has obtained further improving and improving (seeing Table 2)
Table 2 " LIUWEIANXIAO ZHIJI " compares with former preparation " LIUWEIANXIAO JIAONANG " quality standard
Figure C20051006002300081
Useful result: medicine quality standard of the present invention has had raising, and it is controlled more to help constant product quality, and is more conducive to environmental protection.
3, drug efficacy study shows, medicine LIUWEIANXIAO ZHIJI of the present invention has the mice gastric motility of enhancing and analgesic effect, has the protection gastric mucosa of rat and promotes the excretory effect of rat gastric juice.
(1) LIUWEIANXIAO ZHIJI is to the influence of mouse small intestine carbon powder propelling degree
Method: get 70 of white mice, male, random packet, 10/group, be respectively the blank group, LIUWEIANXIAO ZHIJI 3.6,1.8,0.9g/kg (refer to the crude drug amount, down together), LIUWEIANXIAO JIAONANG 3.6,1.8,0.9g/kg dosage group, the blank group gives isopyknic 0.5%CMC-NA, and other each group gives the reagent and the reference substance of corresponding dosage, successive administration 4 days, 0.2ml/10g, once a day, after the last administration 30 minutes, every Mus was irritated stomach 5% carbon powder suspension 0.1ml/10g respectively, the cervical vertebra dislocation is put to death zootomy and is taken out small intestinal after 20 minutes, directly be laid on after peeling off gently on the flat board, measure pylorus to terminal ileum and pylorus to the length in carbon powder forward position, calculate its carbon powder and advance percentage rate.Contrast between organizing, the T check.
Figure C20051006002300091
The result: LIUWEIANXIAO ZHIJI 3.6 and 1.8g/kg group all obviously strengthen the small intestinal peristalsis effect, increase intestinal propulsion, compare with the blank group, difference all has highly significant meaning (P<0.01), LIUWEIANXIAO JIAONANG 3.6g/kg has the effect of obvious enhancing intestinal propulsion, compare with the blank group, difference has significance meaning (P<0.05), sees Table 3.
Table 3 LIUWEIANXIAO ZHIJI is to the influence of mice propelling degree (X ± SD)
Figure C20051006002300092
Compare * * P<0.01, * P<0.05 with the blank group
(2), LIUWEIANXIAO ZHIJI to the atropine sulfate modeling after the influence of mice gastric emptying
Method: get 80 of Kunming kind white mice, male, random packet, is followed successively by the blank group by 10/group, model group, LIUWEIANXIAO ZHIJI 3.6,1.8 and 0.9g/kg dosage group, LIUWEIANXIAO JIAONANG 3.6,1.8 and 0.9g/kg dosage group, the blank group, model group gives 0.5%CMC-NA, and other group gives the reagent and the reference substance of corresponding dosage, 0.2ml/10g, once a day, fasting be can't help water 18 hours before the successive administration 4 days, last administration, and administration is after 45 minutes, equal lumbar injection atropine sulfate 0.3g/kg except that the blank group, respectively organize mice after 15 minutes and all irritate stomach and give test meal, 0.8ml/ only, mice is put to death in the cervical vertebra dislocation after 15 minutes, 1. gastric content residual rate: open abdomen, ligation stomach cardia and pylorus remove stomach, after doing with the filter paper sassafras, claim full weight, cut off along greater gastric curvature then, reuse filter paper sassafras does behind the flush away gastric content, claims net weight, difference with stomach full weight stomach function regulating net weight is the weight of gastric residue, and the percentage by weight that calculating gastric residue accounts for the test meal of irritating is the gastric residual rate.2. intestinal propulsion degree: dissect and get small intestinal, measuring mice pylorus to test meal forward position and pylorus to length of terminal ileum in small intestinal is above-mentioned gained data to be carried out statistical disposition, contrast between organizing, T check for the intestinal propulsion degree.
The result: LIUWEIANXIAO ZHIJI 3.6 and 1.8g/kg all can obviously reduce the amount of mice gastric residue, compare with model group, difference all has significance meaning (P<0.05), LIUWEIANXIAO JIAONANG 3.6,1.8 and 0.9g/kg group all can obviously reduce the amount of mice gastric residue, compare with model group, difference all has highly significant meaning and significance meaning (P<0.01 and P<0.05); LIUWEIANXIAO ZHIJI 3.6,1.8 and 0.9g/kg group, LIUWEIANXIAO JIAONANG 3.6,1.8 and 0.9g/kg group all can obviously increase the propelling degree of mouse small intestine, compare with model group, difference all has highly significant or significance meaning meaning (P<0.01 or P<0.05).See Table 4.
Table 4 LIUWEIANXIAO ZHIJI to the atropine sulfate modeling after the influence (X ± SD) of mice gastric emptying and intestinal propulsion
Figure C20051006002300101
Compare △ P<0.05 with the blank group, compare * P<0.05, * * P<0.01 with model group.
(3), the influence of LIUWEIANXIAO ZHIJI Dichlorodiphenyl Acetate induced mice writhing response
Method: get 70 of white mice, male and female half and half, 10/group, random packet, be divided into the blank group, LIUWEIANXIAO ZHIJI 3.6,1.8 and 0.9g/kg, LIUWEIANXIAO JIAONANG 3.6,1.8 and 0.9g/kg dosage group, except that the blank group awards 0.5%CMC with volume, other each group gives the reagent and the reference substance of corresponding dosage, once a day, and successive administration 4 days, half an hour after the last administration, every Mus lumbar injection 0.5% acetic acid 0.2ml observes the writhing response number of times that each Mus occurs in 20 minutes then, organizes a statistical procedures, contrast between organizing, the T check.
The result: LIUWEIANXIAO ZHIJI 3.6 and 1.8g/kg and LIUWEIANXIAO JIAONANG 3.6g/kg all can obviously reduce the mouse writhing reaction times, compare with the blank group, and difference all has significance or highly significant meaning (P<0.05 or P<0.01).See Table 5.
The influence of writhing response due to the table 5 LIUWEIANXIAO ZHIJI Dichlorodiphenyl Acetate (X ± SD)
Figure C20051006002300111
Compare * P<0.05, * * P<0.01 with the blank group.
(4), LIUWEIANXIAO ZHIJI influences mice hot plate analgesic
Method: get 70 of white mice, female, random packet, 10/group, be respectively the blank group, LIUWEIANXIAO ZHIJI 3.6,1.8 and 0.9g/kg, LIUWEIANXIAO JIAONANG 3.6,1.8 and 0.9g/kg dosage group, the blank group is given isopyknic 0.5%CMC-NA, and other each group gives the reagent and the reference substance of corresponding dosage, once a day, successive administration 4 days, after the last administration 1.5 hours and 2.5 hours, respectively mice is placed on 55 ± 0.5 ℃ the dolorimeter, observe mice from being placed on the hot plate dolorimeter to the time that metapedes occurs licking (pain threshold), 80 seconds nonresponders still, its pain threshold calculated with 80 seconds.Organize a statistical procedures, contrast between organizing, T check.
All can obviously prolong the effect of mice pain threshold in 1.5 hours after result: LIUWEIANXIAO ZHIJI 1.8g/kg, the LIUWEIANXIAO JIAONANG 1.8g/kg administration, compare with the blank group, difference all has significance meaning (P all<0.05); LIUWEIANXIAO ZHIJI 3.6 and 1.8g/kg and LIUWEIANXIAO JIAONANG 1.8 and 0.9g/kg group, after administration, all can obviously prolong the effect of mice pain threshold in 2.5 hours, compare with the blank group, difference all has highly significant or significance meaning (P<0.01 or P<0.05) is arranged, and sees Table 6.
Table 6 LIUWEIANXIAO ZHIJI is to the influence of mice pain threshold (X ± SD)
Figure C20051006002300121
Compare * P<0.05, * * P<0.01 with the blank group.
(5), LIUWEIANXIAO ZHIJI is to the influence of gastric ulcer due to the rat pylorus ligation
Method: get the SD rat, male, be divided into 7 groups at random, 10/group, be followed successively by the blank group, LIUWEIANXIAO ZHIJI 2.16,1.08 and 0.54g/kg and LIUWEIANXIAO JIAONANG 2.16,1.08 with 0.54g/kg dosage group, except that the blank group gives the 0.5%CMC-NA, other each group gives the medicinal liquid of corresponding dosage, 1ml/100g, once a day, successive administration 3 days, fasting be can't help water 48 hours after the first administration, carried out pylorus ligation operation (using etherization) after the last administration in 2.5 hours, the single cage in operation back is placed, and fasting is prohibited water and put to death animal after 16 hours, in the place's ligation of stomach cardia, get its stomach, be put in then in 10% formalin and fix 10 minutes, take out and cut off, be tiled on the flat board along greater gastric curvature, observe the gastric ulcer situation of gastric mucosa, comprise the gastric perforation number, the ulcer number, ulcer inhibition rate and ulcer area, a statistical procedures is organized in statistical disposition, contrast between organizing, the T check.
Figure C20051006002300131
The result: LIUWEIANXIAO ZHIJI 0.54 and 1.08g/kg and LIUWEIANXIAO JIAONANG 1.08g/kg all have the effect of obvious protection pylorus ligation gastric mucosa of rat, the ulcer area is obviously reduced, compare with the blank group, difference all has highly significant or significance meaning (P<0.01 or P<0.05); LIUWEIANXIAO ZHIJI and LIUWEIANXIAO JIAONANG all can improve gastric ulcer suppression ratio due to the rat pylorus ligation, the rat gastric ulcer suppression ratio of LIUWEIANXIAO ZHIJI 2.16,1.08 and 0.54g/kg is followed successively by 31.3%, 37.5%, 62.5%, and the rat gastric ulcer suppression ratio of LIUWEIANXIAO JIAONANG 2.16,1.08 and 0.54g/kg is followed successively by 43.8%, 43.8%, 31.3%.See Table 7.
Table 7 LIUWEIANXIAO ZHIJI is to the influence of rat pyloric ligation ulcers ulcer (X ± SD)
Figure C20051006002300132
Compare * P<0.05, * * P<0.01 with the blank group.
(6), LIUWEIANXIAO ZHIJI is to the excretory influence of rat gastric juice
Method: get the SD rat, male, be divided into 7 groups at random, 10/group, be followed successively by the blank group, LIUWEIANXIAO ZHIJI 2.16,1.08 and 0.54g/kg and LIUWEIANXIAO JIAONANG 2.16,1.08 and 0.54g/kg, except that the blank group gives the 0.5%CMC-NA, other each group gives the medicinal liquid of corresponding dosage, 1ml/100g, once a day, for three days on end, fasting be can't help water 48 hours after the first administration, carried out pylorus ligation operation (using etherization) after the last administration in 2.5 hours, the single cage in operation back is placed, fasting is prohibited water and is put to death animal after 6 hours, dissects the ligation cardia, take out stomach again, cut off along greater gastric curvature, collect its gastric juice, survey its amount; With the 0.1% phenol red indicator of doing, survey the amount of total acidity gastric juice in its 1ml gastric juice, use the Mett method, survey its pepsic activity, carry out statistical disposition, relatively its group difference.
Result: LIUWEIANXIAO ZHIJI 1.08g/kg and 2.16g/kg and LIUWEIANXIAO JIAONANG 0.54g/kg and 2.16g/kg all can obviously increase the rat gastric secretion, compare with the blank group, difference all has significance meaning or highly significant meaning (P<0.05 or P<0.01); LIUWEIANXIAO ZHIJI and LIUWEIANXIAO JIAONANG all do not have obvious influence to rat total acidity gastric juice and pepsin output thereof, with the blank group relatively, difference there are no significant meaning (P>0.05) sees Table 8.
Table 8 LIUWEIANXIAO ZHIJI is to the excretory influence of rat gastric juice (X ± SD)
Figure C20051006002300141
Compare * P<0.05, * * P<0.01 with the blank group.
The specific embodiment
Embodiment
Take by weighing raw material by following proportioning:
250 parts of 100 parts of Gypsum Rubrum (calcined) of 200 parts of Rhizoma Kaempferiae of 50 parts of Radix Et Rhizoma Rhei of Radix Inulae
300 parts of 150 parts of trona of Fructus Chebulae
(1), above Six-element, get Gypsum Rubrum (calcined) earlier and be ground into fine powder, it is standby to cross 80 mesh sieves;
(2), trona with the heating of 6 times of water gagings decoct make dissolving after, filter, the filtrate water-bath concentrates, it is dry that must to make with extra care thing standby;
(3), Radix Inulae, Radix Et Rhizoma Rhei, Rhizoma Kaempferiae and Fructus Chebulae powder are broken into coarse powder, make solvent, soak after 24 hours and carry out percolation, collect the liquid of filtering with 90% ethanol.The percolate decompression (70 ℃, 0.07KPa) behind the recovery ethanol, reconcentration to relative density is the thick paste of 1.20~1.25 (60 ℃);
(4), (3) gained thick paste is added (1) gained fine powder, mixing, decompression (50 ℃, 0.07KPa) drying;
(5), the dry thing of (4) gained is added the refining thing of (2) gained trona, be ground into fine powder (crossing 80 mesh sieves), make granule with ethanol, dry (50 ℃, 0.07KPa), 24 mesh sieve granulate incapsulate, promptly.

Claims (16)

1. treatment stomachache distension, dyspepsia, constipation, the gastric motility Chinese medicine preparation of dysmenorrhea is characterized in that it is made as follows by following raw medicaments in portion by weight:
210~410 parts of 110~210 parts of trona of 145~360 parts of Fructus Chebulaes of 65~155 parts of Gypsum Rubrum (calcined) of 130~300 parts of Rhizoma Kaempferiae of 30~70 parts of Radix Et Rhizoma Rhei of Radix Inulae;
(1), Gypsum Rubrum (calcined) is ground into fine powder, it is standby to cross 40~100 mesh sieves;
(2), trona with the heating of 2~8 times of water gagings decoct make dissolving after, filter, filtrate concentrates, dry thing is standby;
(3), Radix Inulae, Radix Et Rhizoma Rhei, Rhizoma Kaempferiae and Fructus Chebulae powder are broken into coarse powder, make solvent with 60~95% ethanol, flood and carry out percolation after 12~72 hours, collect the liquid of filtering, percolate is concentrated into the thick paste shape after reclaiming ethanol;
(4), (3) gained thick paste is added (1) gained fine powder, mixing, drying under reduced pressure;
(5), the dry thing of (4) gained is added the refining thing of (2) gained trona, be ground into fine powder;
(6), with above-mentioned dry thing, make acceptable various dosage forms on the pharmaceutics according to a conventional method.
2. preparation according to claim 1 is characterized in that the weight proportion of crude drug wherein is:
240~360 parts of 130~170 parts of trona of 195~295 parts of Fructus Chebulaes of 85~135 parts of Gypsum Rubrum (calcined) of 160~240 parts of Rhizoma Kaempferiae of 40~60 parts of Radix Et Rhizoma Rhei of Radix Inulae.
3. preparation according to claim 2 is characterized in that the weight proportion of crude drug wherein is:
300 parts of 150 parts of trona of 250 parts of Fructus Chebulaes of 100 parts of Gypsum Rubrum (calcined) of 200 parts of Rhizoma Kaempferiae of 50 parts of Radix Et Rhizoma Rhei of Radix Inulae.
4. according to the arbitrary described preparation of claim 1~3, it is characterized in that: the dosage form of described preparation is: capsule, granule, tablet, oral liquid or pill.
5. preparation according to claim 4 is characterized in that: described dosage form is a capsule.
6. the preparation method of the described preparation of claim 5 is characterized in that comprising the steps:
(1), get Gypsum Rubrum (calcined) and be ground into fine powder, it is standby to cross 40~80 mesh sieves;
(2), get trona with the heating of 2~8 times of water gagings decoct make dissolving after, filter, the filtrate water-bath concentrates, it is dry that must to make with extra care thing standby;
(3), the Radix Aucklandiae that fetches earth, Radix Et Rhizoma Rhei, Rhizoma Kaempferiae and Fructus Chebulae powder be broken into coarse powder, makes solvent with 60~95% ethanol, floods and carry out percolation after 12~72 hours, collects the liquid of filtering.After percolate reclaimed ethanol, reconcentration was to thick paste;
(4), (3) gained thick paste is added (1) gained fine powder, mixing, drying;
(5), the dry thing of (4) gained is added the refining thing of (2) gained trona, be ground into fine powder, make granule with ethanol, drying, 24 mesh sieve granulate incapsulate, promptly.
7. preparation method according to claim 6 is characterized in that: method for concentration wherein is to concentrate under the normal pressure.
8. preparation method according to claim 7 is characterized in that: method for concentration wherein is that water-bath concentrates under the normal pressure.
9. preparation method according to claim 6 is characterized in that: method for concentration wherein is a concentrating under reduced pressure, and the concentrating under reduced pressure condition is: 0.01~0.09KPA, 40~90 ℃.
10. preparation method according to claim 6 is characterized in that: recovery solvent method wherein is that normal pressure reclaims.
11. preparation method according to claim 6 is characterized in that: recovery solvent method wherein is a reclaim under reduced pressure, and the condition of decompression and solvent recovery is: 0.01~0.09KPA, 30~80 ℃.
12. preparation method according to claim 11 is characterized in that: the condition of said decompression and solvent recovery method is: 0.07KPa, 70 ℃.
13. preparation method according to claim 6 is characterized in that: drying means wherein is: contact drying, pneumatic conveying drying, tunnel type oven drying, drying under reduced pressure, airpillow-dry, spray drying, lyophilization, far-infrared ray drying or microwave drying.
14. preparation method according to claim 13 is characterized in that: drying means wherein is a drying under reduced pressure, and the condition of drying under reduced pressure is: 0.01~0.09KPA, 40~90 ℃.
15. preparation method according to claim 14 is characterized in that: drying means wherein is a drying under reduced pressure, and the condition of drying under reduced pressure is: 0.07KPA, 50 ℃.
16., it is characterized in that preparation technology wherein is according to the arbitrary described preparation method of claim 6~15:
(1), get Gypsum Rubrum (calcined) and be ground into fine powder, it is standby to cross 80 mesh sieves;
(2), trona with the heating of 6 times of water gagings decoct make dissolving after, filter, the filtrate water-bath concentrates, it is dry that must to make with extra care thing standby;
(3), Radix Inulae, Radix Et Rhizoma Rhei, Rhizoma Kaempferiae and Fructus Chebulae powder are broken into coarse powder, make solvent, flood and carry out percolation after 24 hours, collect the liquid of filtering with 90% ethanol.Behind the percolate decompression recycling ethanol, reconcentration to relative density is the thick paste of 1.20~1.25 (60 ℃);
(4), (3) gained thick paste is added (1) gained fine powder, mixing, drying under reduced pressure;
(5), the dry thing of (4) gained is added the refining thing of (2) gained trona, be ground into fine powder, make granule with ethanol, drying, 24 mesh sieve granulate incapsulate, promptly.
CNB2005100600232A 2004-08-31 2005-03-24 Stomach-power Chinese medicine preparation and preparing method Expired - Fee Related CN100408058C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005100600232A CN100408058C (en) 2004-08-31 2005-03-24 Stomach-power Chinese medicine preparation and preparing method

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200410075381.6 2004-08-31
CN200410075381 2004-08-31
CNB2005100600232A CN100408058C (en) 2004-08-31 2005-03-24 Stomach-power Chinese medicine preparation and preparing method

Publications (2)

Publication Number Publication Date
CN1742820A CN1742820A (en) 2006-03-08
CN100408058C true CN100408058C (en) 2008-08-06

Family

ID=36138445

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100600232A Expired - Fee Related CN100408058C (en) 2004-08-31 2005-03-24 Stomach-power Chinese medicine preparation and preparing method

Country Status (1)

Country Link
CN (1) CN100408058C (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526574A (en) * 2011-12-28 2012-07-04 江西青春康源制药有限公司 Traditional Chinese medicine preparation-Liuwei Anxiao Pills and preparing method thereof
CN110721194A (en) * 2019-12-03 2020-01-24 平措绕吉 Method for processing Tibetan trona as medicine
CN112999172B (en) * 2021-03-26 2023-07-21 那生桑 Mineral Mongolian medicinal powder formula granule and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1365768A (en) * 2001-01-19 2002-08-28 杨孟君 Nano 6-component Anxiao medicine and its preparing process
CN1456225A (en) * 2003-01-22 2003-11-19 毛友昌 Preparation of six component medicine against food stagnancy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1365768A (en) * 2001-01-19 2002-08-28 杨孟君 Nano 6-component Anxiao medicine and its preparing process
CN1456225A (en) * 2003-01-22 2003-11-19 毛友昌 Preparation of six component medicine against food stagnancy

Also Published As

Publication number Publication date
CN1742820A (en) 2006-03-08

Similar Documents

Publication Publication Date Title
CN102813801B (en) Traditional Tibetan medicine for treating cough and preparation method thereof
CN101637561A (en) Fritillary-loquat medicinal composition and preparation method thereof
CN102362966A (en) Unibract fritillary bulb and loquat leaf medicinal composition and preparation method thereof
CN103127443A (en) Pharmaceutical composition for adjuvant therapy of cancers and preparation method thereof
CN100408058C (en) Stomach-power Chinese medicine preparation and preparing method
CN101703691B (en) Chinese medicinal composition for treating gastrointestinal ulcer and hemorrhage, and preparation method thereof
CN100509034C (en) Medicine for treating chronic atrophic gastritis
CN1907335B (en) Pharmaceutical composition for treating nasosinusitis and its preparing process
CN101700296B (en) Chinese herbal preparation for curing gastroenteritis and preparation method thereof
CN103816482A (en) Traditional Chinese medicine mixture for treating thyroid enlargement as well as preparation method and application thereof
CN104547683B (en) A kind of Chinese medicine composition for treating chronic gastritis and preparation method thereof
CN106983795A (en) Chinese medicine composition with antitumor activity and its preparation method and application
CN101879227B (en) Chinese medicinal composition for treating protrusion of lumbar intervertebral disci and preparation method thereof
CN102579558B (en) Application of bauhinia championii total flavonoids in preparation of medicine for treating rheumatoid arthritis
CN100534498C (en) Pharmaceutical composition used for chronic atrophic gastritis and preparation method thereof
CN101474277B (en) Medicine composition for rheumatism and its preparation
CN101433649A (en) Composition for treating gall stone symptom
CN104274800A (en) Medicine for treating gastric diseases and preparation method thereof
CN104000969B (en) A kind of Chinese materia medica preparation for treating children's intestines system lymphonodi abdominales inflammation
CN101954032B (en) Pure traditional Chinese medicinal preparation for treating gastric motility disorder
CN100425280C (en) Chinese medicinal composition for treating rheumatoid arthritis
CN106389680A (en) Solid dispersion for treating peptic ulcer
CN1180835C (en) Medicine for treating dysmenorrhea and its preparing method
CN102940818A (en) Medicine composition for treating dyspepsia
CN102961678B (en) Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: JIANGXI YINTAO DRUG INDUSTRY CO., LTD.

Free format text: FORMER OWNER: JIANGXI PROV. MEDICINE INST.

Effective date: 20090410

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20090410

Address after: 36, Linchuan Avenue, Fuzhou, Jiangxi, 344100

Patentee after: Yintao Pharmaceutical Industry Co., Ltd., Jiangxi

Address before: 181, Nanjing East Road, East Lake District, Nanchang, Jiangxi, zip code: 330029

Co-patentee before: Yintao Pharmaceutical Industry Co., Ltd., Jiangxi

Patentee before: Jiangxi Institute of drug research

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080806

Termination date: 20140324